| abstract |
REFERRING TO A COMPOUND DERIVED FROM ISOQUINOLONE 6-PIPERIDINYL OF FORMULA (I), WHERE R1 IS H, C1-C6 ALKYL, C2-C6 ALKENYL, AMONG OTHERS; R2 IS H, C1-C6 ALKYL, (C1-C6 ALKYLENE) 0-1-O- (C1-C6 ALKYL), AMONG OTHERS; R3 IS H, HALOGEN, CN, OH, NH2, AMONG OTHERS; R4 IS H, HYDROXY, HALOGEN, CN, C3-C8 CYCLOALKYL, AMONG OTHERS; R5 IS H, HALOGEN, CN, NO2, C1-C6 ALKYL, AMONG OTHERS; R6 IS H, C1-C8 ALKYL, (C1-C6 ALKYLENE) -OR- (C1-C6 ALKYL), AMONG OTHERS; R7 AND R8 ARE EACH H, HALOGEN, CN, C1-C6 ALKYL, AMONG OTHERS, R9 IS HALOGEN, C1-C6 ALKYL; n IS 0-4; L IS O, O-C1-C6 ALKYLENE. PREFERRED COMPOUNDS ARE: N- (2,2-DIMETOXY-ETHYL) -N- (4-FLUORO-BENZYL) -4-METHYL-BENZENE-SULFONAMIDE; TERC-BUTYL ESTER OF 4- (ISOQUINOLIN-6-ILOXI) -PIPERIDINE-1-CARBOXYL ACID; AMONG OTHERS. ALSO REFERRED TO A PHARMACEUTICAL COMPOSITION AND A PREPARATION PROCEDURE. SUCH COMPOUNDS ARE INHIBITORS OF RhO-KINASE AND ARE USEFUL IN THE TREATMENT AND / OR PREVENTION OF CARDIOVASCULAR AND NON-CARDIOVASCULAR DISEASES, SUCH AS HYPERTENSION, RETINOPATHY, AMONG OTHERS |